Ajinomoto Co., Ltd.

Ea Pharma Co., Ltd.

Masayuki Sugiki

Toru Okamatsu

Tetsuo Yano

Tamotsu Suzuki

Tatsuya Okuzumi

Noriyasu Kataoka

Tatsuhiro Yamada

Uno Tagami

Koichi Fujita

Kazuyuki Sagi

Munetaka Tokumasu

Yoichiro Shima

Itsuya Tanabe

Misato Noguchi

Shunsuke Kageyama

Akira Nakayama

Hiroki Yamaguchi

Yasuhiro Tanaka

Yuzuru Eto

Yasuhiro Mihara

Toshihiro Hatanaka

Akinori Tatara

Sayaka Asari

Naohiro Miyamura

Hiroaki Nagasaki

Reiko Yasuda

Yayoi Kawato

Tomoko Shimizu

Takayuki Ito

Takashi Yamamoto

Hideki Matsumoto

Koji Ohsumi

Tadakiyo Nakagawa

Toshihiko Yoshimura

Manabu Kitazawa

Naoyuki Fukuchi

Ayako Sato

Natalia Viktorovna Stoynova

Mitsuo Takahashi

Sergey Vasilievich Smirnov

Shinya Taniguchi

Kotaro Okado

Shogo Nakano

Kunio Nakata

Chihiro Tsuji

Tomoharu Motoyama

Kaori Kobayashi

Ayatoshi Andou

Hajime Ito

Yoriko Yamamoto

Sohei Ito

Kenji Shinkai

Yukie Seki

Tatsuki Kashiwagi

Takashi Kayahara

Shunji Takehana

Kohichi Fujita

Kuniya Sakurai

Hiroaki Fukada

Haruko Hirashima

Akiko Oonuki

Elena Viktorovna Sycheva

Kazuyuki Ubukata

Toshihiko Sugiura

Ayatoshi Ando

Tomoko Miyazawa

Daiki Yahagi

Mitsunori Tokura

Kazumi Tashiro

Tomohiro Fujii

Hirokazu Ueno

Ryohei Yokoyama

Agung Eviryanti

Yasuko Nogi

Erika Yoshida

Manami Shuto

Eri Higashiura

Misato Okamoto

Erika Watanabe

Yuki Oda

Mizuki Kawahira

Ryuta Takashita

Hiroyuki Eda

Aya Kirihara

Tarou Nakamura

Mizuki Dohi

Elena V Matrosova

Natalia V Geraskina

The present invention provides a mutated histidine decarboxylase suitable for a practical use. Specifically, the present invention provides a mutated histidine decarboxylase having at least one amino acid residue mutated as compared to a wild-type histidine decarboxylase, and having higher histidine decarboxylase activity and/or stability than the wild-type histidine decarboxylase, and also a use thereof. The mutated histidine decarboxylase has Motifs (1) to (6), and an amino acid residue in at least one motif thereof can be mutated. The mutated histidine decarboxylase can also have a mutation of at least one amino acid residue in an amino acid sequence designated by SEQ ID NO: 3 and in a homologous sequence thereto.

Mutated histidine decarboxylase and use thereof

The present invention provides a 2-OST mutant exhibiting a high activity. Specifically, the present invention provides a 2-O-sulfation enzyme mutant, having a substitution of a leucine residue at position 321 with a basic amino acid residue in any one amino acid sequence of: (a) the amino acid sequence of SEQ ID NO: 2; (b) an amino acid sequence comprising one or several amino acid substitutions, deletions, insertions, or additions in the amino acid sequence of SEQ ID NO: 2; (c) an amino acid sequence having 90% or more identity to the amino acid sequence of SEQ ID NO: 2; (d) the amino acid sequence consisting of amino acid residues at positions 69 to 356 in the amino acid sequence of SEQ ID NO: 2; (e) an amino acid sequence comprising one or several amino acid substitutions, deletions, insertions, or additions in the amino acid sequence consisting of amino acid residues at positions 69 to 356 in the amino acid sequence of SEQ ID NO: 2; (f) an amino acid sequence having 90% or more identity to the amino acid sequence consisting of amino acid residues at positions 69 to 356 in the amino acid sequence of SEQ ID NO: 2; and having a 2-O-sulfate transfer activity.

2-O-sulfation enzyme mutant and 3-O-sulfation enzyme mutant, and method for using same

A composition containing a compound represented by General Formula (I) below (see the definition in the specification for the symbols in the formula) or a salt thereof has an excellent CaSR agonistic effect and provides a pharmaceutical agent, a CaSR agonistic agent, a prophylactic or therapeutic agent for a disease that can be ameliorated through CaSR activation as well as seasonings and an agent for imparting kokumi.

Alkylamine derivative

A method for producing an objective protein and a method for producing a disaccharide are provided. An objective protein is produced by culturingin a culture medium containing an expression inducer such as gentiobiose. A disaccharide is produced from a saccharide raw material by enzymatic conversion using a disaccharide synthesizing enzyme.

Method for producing a protein and disaccharide using a

A mutant glutathione synthetase (GSHB) suitable for generating &#x3b3;-Glu-Val-Gly, and a method for producing &#x3b3;-Glu-Val-Gly using the same are provided. &#x3b3;-Glu-Val-Gly is produced by using a mutant GSHB having a mutation at such a position as V7, N13, I14, N15, K17, F22, F95, M165, N199, Y200, P202, I274, T285, and P287.

Mutant glutathione synthetase and method for producing gamma-glutamyl-valyl-glycine

A composition containing a compound represented by General Formula (I) below (see the definition in the specification for the symbols in the formula) or a salt thereof has an excellent CaSR agonistic effect and provides a pharmaceutical agent, a CaSR agonistic agent, a prophylactic or therapeutic agent for a disease that can be ameliorated through CaSR activation as well as seasonings and an agent for imparting kokumi. 

Sulfonamide compounds of a specific chemical structure in which a sulfonamide group having, as a substituent, a phenyl group or a heterocyclic group having a hetero atom(s) as a constituent element(s) is present at its terminal, and pharmaceutically acceptable salts thereof. These compounds are novel compounds having excellent &#x3b1;4 integrin-inhibitory action. The compounds have formulae represented by: 

Sulfonamide derivative and medicinal use thereof

By searching various kinds of compounds having CaSR agonistic activity, the present invention provides CaSR agonistic agents, pharmaceutical compositions, preventive or therapeutic agents for diarrhea and kokumi-imparting agents each of which comprise the compound. More specifically, the present invention provides CaSR agonistic agents, pharmaceutical compositions, preventive or therapeutic agents for diarrhea and kokumi-imparting agents each of which comprise a glutamic acid derivative having CaSR agonistic activity or pharmaceutically acceptable salts thereof.

CaSR agonists

Compounds having an excellent CaSR agonist activity are in demand. The invention provides glutamate derivatives or salts thereof, pharmaceutical compositions comprising the glutamate derivatives, preventive or therapeutic agents for diarrhea, hyperparathyroidism or peptic ulcer.

Glutamate derivatives or salts thereof

A method for preparing a phenylalanine derivative having a quinazoline-dione ring represented by the following formula (1) or a pharmaceutically acceptable salt thereof, comprising the following steps (a), (b) and (c):  with a carbonyl group-introducing reagent and a specific anthranilic acid derivative to thus form the corresponding carboxy-asymmetric urea derivative;

Method for preparing phenylalanine derivatives having quinazoline-dione skeleton and intermediates for use in the preparation of the derivatives

Specific phenylalanine derivatives and analogues thereof have an antagonistic activity to &#x3b1;4 integrin. They are used as therapeutic agents for various diseases concerning &#x3b1;4 integrin.

Phenylalanine derivatives

Growing community of inventors

Kawasaki, Japan

Masayuki Sugiki